On 22nd May 2019, Algeria and Argentina have been officially recognized by WHO as malaria-free. The certification is granted when a country proves that it has interrupted indigenous transmission of the disease for at least 3 consecutive years.
On April 23rd, the Government of Malawi launched the world’s first malaria vaccine pilot programme. Together with Ghana and Kenya, which will also introduce the vaccine in the coming weeks, the RTS,S vaccine will be made available to children up to 2 years of age, testing a new promising tool to be added to the already existing tools in an effort to get the malaria response back on track.
WHO is undertaking a consultative process to solicit inputs into a prioritization framework for the research and development (R&D) of malaria health products. A draft report “Analysis of Malaria R&D Priorities” identifies five key challenges that represent threats or barriers to achieving the WHO Global Technical Strategy for Malaria 2016–2030 goals. This early copy of the report is being shared at a time when WHO is exploring how best to guide and support the development of priority solutions to meet public health needs.
Another MESA grantee has finalised its projects and shared the findings: the MESA-funded IVERMAL Study, a randomised, double-blind, placebo-controlled trial conducted in Kenya and led by the Liverpool School of Tropical Medicine (LSTM) has produced new evidence that supports the use of ivermectin as a tool for malaria elimination.
More than 180 scientists, malaria programme managers and policy makers from around the world have come together through a consultative process to update the research agenda for malaria elimination and eradication, first produced in 2011. The outcome is a series of seven ‘malERA Refresh’ (malaria eradication research agenda) papers that have undergone expert peer review and will soon be published in an open access journal.